Table 2 Statin therapy and rVTE.

From: Statin therapy and recurrent venous thromboembolism in the elderly: a prospective cohort study

Number of events/Number of patients

Analysis

Crude subhazard ratio (95%-CI)

p-value

Adjusted subhazard ratio (95%-CI)

p-value

 

Traditional statistical analysis approach

    

120/980

Overall

0.62 (0.39 to 1.00)

0.049

0.72 (0.44 to 1.19)a

0.197

31/972

Periods with AC

1.16 (0.54 to 2.49)

0.707

1.34 (0.54 to 3.35)a

0.525

89/595

Periods without AC

0.52 (0.28 to 0.95)

0.034

0.50 (0.27 to 0.92)a

0.027

 

Sensitivity analysis including same variables as the propensity score approach

  

0.60 (0.36 to 1.01)b

0.056

 

Including markers of inflammation

    

120/980

Fibrinogen

  

0.75 (0.45 to 1.23)c

0.250

120/980

ultrasensitive CRP

  

0.72 (0.43 to 1.19)c

0.197

 

Propensity score weighted approach d

    

99/792

Overall

0.60 (0.34 to 1.03)

0.064

0.42 (0.21 to 0.81)e

0.010

28/788

Periods with AC

1.34 (0.60 to 3.01)

0.481

1.17 (0.47 to 2.90)e

0.740

71/477

Periods without AC

0.38 (0.18 to 0.84)

0.016

0.20 (0.08 to 0.49)e

<0.001

 

Including markers of inflammation

    

99/792

Fibrinogen

  

0.43 (0.22 to 0.84)c

0.014

99/792

ultrasensitive CRP

  

0.41 (0.21 to 0.80)c

0.009

  1. AC = anticoagulation, CRP = C-Reactive Protein.
  2. aAdjusted for age, gender, symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous thromboembolism, cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, transient ischaemic attack] disease), active cancer, and periods of anticoagulation as a time-varying covariate.
  3. bSensitivity analysis: further adjustment for the same variables as used in the propensity score approach. Adjusted to include age, gender, symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous thromboembolism, cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, transient ischaemic attack] disease), active cancer, periods of anticoagulation as a time-varying covariate, and additionally hypertension, polypharmacy, smoking (never/past/current), body-mass index (≥25).
  4. cTwo separate additional adjustment variables: log-Fibrinogen and log-ultrasensitive C-Reactive Protein (as potential explanatory variables of the association between statins and rVTE). Multiple imputation for missing values of fibrinogen and ultrasensitive C-Reactive Protein was performed.
  5. dVariables used to calculate the propensity score: age, gender, symptomatic pulmonary embolism, prior venous thromboembolism, provoked venous thromboembolism, cardiovascular disease (i.e. coronary heart, peripheral arterial or cerebrovascular [stroke, transient ischaemic attack] disease), active cancer, hypertension, polypharmacy, smoking (never/past/current), and body-mass index (≥25).
  6. eThe adjusted model was weighted according to inverse probability of treatment weights (IPTW) and additionally adjusted for periods of anticoagulation as a time-varying covariate.
Back to article page